Colorectal cancer (CRC) is one of the commonest malignant disorders and frequently associated with high expression of epidermal growth factor receptor (EGFR), resulting in advanced disease and a poor prognosis. In this study, we investigated the radiosensitizing effects of the selective EGFR inhibitor cetuximab in human CRC cell lines.
Methods
Four human CRC cell lines, CaCo-2, HCT-8, LoVo, and WiDr, were treated with cetuximab and/or radiation. The effects on cell proliferation and viability were measured by MTT and annexin-V staining, and clonogenic survival assay. The in vivo effect on the growth of CRC xenografts was assessed in athymic nude mice.
Results
Cetuximab in combination with radiation significantly inhibited the in vitro proliferation of CRC cells, with a concomitant increase in cell death, except in WiDr cells. Clonogenic survival assay confirmed that cetuximab worked as a radiosensitizer in three cetuximab-sensitivie CRC cells. However, no correlations were found between the radiosensitivity and EGFR expression level or mutation status of EGFR signaling molecules. In nude mice bearing CRC cell xenografts, cetuximab plus radiation significantly inhibited the tumor growth over either agent alone. Interestingly, the WiDr xenograft was also sensitive to cetuximab and/or radiation in vivo, suggesting host-mediated effects of cetuximab.
Conclusions
Cetuximab enhanced the radiosensitivity of CRC cells in vitro and efficiently inhibited xenograft tumor growth. This study provided a rationale for the clinical application of the selective EGFR inhibitor cetuximab in combination with radiation in CRC. Free full text available at www.tumorionline.it
KamangarF., DoresG.M., AndersonW.F.: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24: 2137–2150, 2006.
2.
LeeJ.C., WangS.T., ChowN.H., YangH.B.: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer, 38: 1065–1071, 2002.
3.
UllrichA., SchlessingerJ.: Signal transduction by receptors with tyrosine kinase activity. Cell, 61: 203–212, 1990.
4.
CarpenterG.: The EGF receptor: a nexus for trafficking and signaling. Bioessays, 22: 697–707, 2000.
5.
YardenY.: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer, 37(Suppl 4): S3–8, 2001.
6.
KlapperL.N., KirschbaumM.H., SelaM., YardenY.: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res, 77: 25–79, 2000.
7.
MendelsohnJ.: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer, 8: 3–9, 2001.
8.
De LucaA., ArraC., D'AntonioA., CasamassimiA., LositoS., FerraroP., CiardielloF., SalomonD.S., NormannoN.: Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene, 19: 5863–5871, 2000.
9.
WaksalH.W.: Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev, 18: 427–436, 1999.
10.
ZhuZ.: Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin, 28: 1476–1493, 2007.
DentP., ReardonD.B., ParkJ.S., BowersG., LogsdonC., ValerieK., Schmidt-UllrichR.: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell, 10: 2493–2506, 1999.
13.
MilasL., MasonK., HunterN., PetersenS., YamakawaM., AngK., MendelsohnJ., FanZ.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res, 6: 701–708, 2000.
14.
RabenD., HelfrichB., ChanD.C., CiardielloF., ZhaoL., FranklinW., BaronA.E., ZengC., JohnsonT.K., Bunn PAJ.r.: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res, 11: 795–805, 2005.
15.
HuangS.M., HarariP.M.: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res, 6: 2166–2174, 2000.
16.
HarariP.M., HuangS.M.: Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys, 49: 427–433, 2001.
17.
BonnerJ.A., HarariP.M., GiraltJ., AzarniaN., ShinD.M., CohenR.B., JonesC.U., SurR., RabenD., JassemJ., OveR., KiesM.S., BaselgaJ., YoussoufianH., AmellalN., RowinskyE.K., AngK.K.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354: 567–578, 2006.
CiardielloF., TortoraG.: EGFR antagonists in cancer treatment. N Engl J Med, 358: 1160–1174, 2008.
24.
ScartozziM., BearziI., BerardiR., MandolesiA., FabrisG., CascinuS.: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol, 22: 4772–4778, 2004.
25.
MoroniM., VeroneseS., BenvenutiS., MarrapeseG., Sartore-BianchiA., Di NicolantonioF., GambacortaM., SienaS., BardelliA.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol, 6: 279–286, 2005.
26.
LayfieldL.J., BernardP.S., GoldsteinN.S.: Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma. J Surg Oncol, 83: 227–231, 2003.
27.
PetrovaD., JankovaR., YosifovaA., TzenovaV., DimovaI., TonchevaD.: Tissue microarray analysis of EGFR gene amplification and gain in Bulgarian patients with colorectal cancer. Onkologie, 29: 198–200, 2006.
28.
ShiaJ., KlimstraD.S., LiA.R., QinJ., SaltzL., Teruya-FeldsteinJ., AkramM., ChungK.Y., YaoD., PatyP.B., GeraldW., ChenB.: Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol, 18: 1350–1356, 2005.
29.
LievreA., BachetJ.B., Le CorreD., BoigeV., LandiB., EmileJ.F., CoteJ.F., TomasicG., PennaC., DucreuxM., RougierP., Penault-LlorcaF., Laurent-PuigP.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66: 3992–3995, 2006.
30.
ZhangW., GordonM., SchultheisA.M., YangD.Y., NagashimaF., AzumaM., ChangH.M., BoruckaE., LurjeG., SherrodA.E., IqbalS., GroshenS., LenzH.J.: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol, 25: 3712–3718, 2007.
31.
PerrotteP., MatsumotoT., InoueK., KuniyasuH., EveB.Y., HicklinD.J., RadinskyR., DinneyC.P.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res, 5: 257–265, 1999.
32.
PrewettM.C., HooperA.T., BassiR., EllisL.M., WaksalH.W., HicklinD.J.: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res, 8: 994–1003, 2002.
33.
MachielsJ.P., SempouxC., ScallietP., CocheJ.C., HumbletY., Van CutsemE., KergerJ., CanonJ.L., PeetersM., AydinS., LaurentS., KartheuserA., CosterB., RoelsS., DaisneJ.F., HonhonB., DuckL., KirkoveC., BonnyM.A., HaustermansK.: Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol, 18: 738–744, 2007.
34.
BertoliniF., ChiaraS., BengalaC., AntognoniP., DealisC., ZironiS., MalavasiN., ScolaroT., DepenniR., JovicG., SonaglioC., RossiA., LuppiG., ConteP.F.: Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 73: 466–472, 2009.
